Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Bristol-Myers Squibb is acquiring worldwide rights to research, develop, and commercialize biologics based on Ambrx’ Fibroblast Growth Factor 21 (FGF-21) protein, a potential treatment for type 2 diabetes, and the hormone relaxin for potential use in treating heart failure. BMS will pay Ambrx $24 million up front and may make milestone and royalty payments. FGF-21 is in late-stage preclinical studies. Relaxin is a naturally occurring hormone known for its role in pregnancy and childbirth. It has been shown in preclinical studies to improve cardiac function.
This article has been sent to the following recipient: